Softdeal Pharmaceutical Private Limited, a active private limited company, was established on 25 January 2006 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U51900MH2006PTC159237. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹0.10 M and a paid-up capital of ₹0.10 M.
Formerly known as Softdeal Trading Company Private Limited. It upholds a compliant status. Employing 78 professional, Its leadership includes Rakeshchandra Jagdishprasad Sinha (Director), Prince Kalarickal Elias (Director), Kedar Nath Senapati (Director). Past directors included Chandrakant Khubchandbhai Agrawal, Suresh Kumar Ajmera, Rakeshchandra Jagdishprasad Sinha. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Acme Plaza, Andheri - Kurla Road Andheri (East), Mumbai, Maharashtra, 400059.
U51900MH2006PTC159237
159237
25 January 2006
₹0.10 M
₹0.10 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Softdeal Pharmaceutical Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rakeshchandra Jagdishprasad Sinha | Director | 19 Apr 2019 | Current |
| Prince Kalarickal Elias | Director | 29 Jan 2024 | Current |
| Kedar Nath Senapati | Director | 21 Feb 2022 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 28 Sep 2013 | Past |
| Pramod Abcsdd | Director | 03 May 2019 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2019 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2024 | Past |
| Pramod Abcsdd | Additional Director | 29 Sep 2012 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2021 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Softdeal Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.53% decrease. The company also saw a slight decrease in profitability, with a 7.16% decrease in profit. The company's net worth Soared by an impressive increase of 90.81%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Softdeal Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Softdeal Pharmaceutical has a workforce of 78 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Softdeal Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Softdeal Pharmaceutical's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Softdeal Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was completed.
The activity Softdeal Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was completed.
Progress on Prince Kalarickal Elias was appointed as a Director was appointed as a Director on 29 Jan 2024 & has been associated with this company since 1 year 10 months . was documented.
Kedar Nath Senapati was appointed as a Director was appointed as a Director on 21 Feb 2022 & has been associated with this company since 3 years 9 months . was recorded as a recent event.
Progress on Rakeshchandra Jagdishprasad Sinha was appointed as a Director was appointed as a Director on 19 Apr 2019 & has been associated with this company since 6 years 7 months . was documented.
The activity Softdeal Pharmaceutical Private Limited was registered on 25 Jan 2006 with Roc Mumbai & aged 19 years 10 months as per MCA records. was completed.
The CIN of Softdeal Pharmaceutical Private Limited is U51900MH2006PTC159237.
Softdeal Pharmaceutical Private Limited is headquartered at Acme Plaza, Andheri - Kurla Road Andheri (East), Mumbai, Maharashtra, 400059.
Softdeal Pharmaceutical Private Limited was incorporated on 25 January 2006.
The current directors of Softdeal Pharmaceutical Private Limited are
The primary industry of Softdeal Pharmaceutical Private Limited is Trade.
Softdeal Pharmaceutical Private Limited is unlisted.
The authorized capital of Softdeal Pharmaceutical Private Limited is ₹0.10 M, and the paid-up capital is ₹0.10 M.
The compliance status of Softdeal Pharmaceutical Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX